-
Je něco špatně v tomto záznamu ?
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
L. Moreno, H. Caron, B. Geoerger, A. Eggert, G. Schleiermacher, P. Brock, D. Valteau-Couanet, L. Chesler, JH. Schulte, K. De Preter, J. Molenaar, A. Schramm, M. Eilers, T. Van Maerken, JI. Johnsen, M. Garrett, SL. George, DA. Tweddle, P. Kogner,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
- MeSH
- časové faktory MeSH
- cílená molekulární terapie MeSH
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- neuroblastom farmakoterapie patologie MeSH
- preklinické hodnocení léčiv metody MeSH
- prognóza MeSH
- protinádorové látky škodlivé účinky farmakologie MeSH
- racionální návrh léčiv * MeSH
- randomizované kontrolované studie jako téma MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
INTRODUCTION: Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively small numbers of patients. Areas covered: The current drug development model has been slow, associated with significant attrition, and few new drugs have been developed for neuroblastoma. The Neuroblastoma New Drug Development Strategy (NDDS) has: 1) established a group with expertise in drug development; 2) prioritised targets and drugs according to tumour biology (target expression, dependency, pre-clinical data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3) promoted clinical trials with target-prioritised drugs. Drugs showing activity can be rapidly transitioned via parallel randomised trials into front-line studies. Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.
Emma Children's Hospital Amsterdam Netherlands e Hoffman La Roche Basel Switzerland
f Department of Paediatric and Adolescent Oncology Institut Gustave Roussy Villejuif France
g Department of Pediatric Oncology and Hematology Charite University Hospital Berlin Germany
i Department Paediatric Oncology Great Ormond Street Hospital London UK
k Centre for Medical Genetic Ghent University Ghent Belgium
l Princess Maxima Center for Pediatric Oncology University of Amsterdam Amsterdam Netherlands
m Department of Pediatric Oncology University of Essen Essen Germany
o Department of Women's and Children's Health Karolinska Institute Stockholm Sweden
p School of Biosciences University of Kent Canterbury UK
q Wolfson Childhood Cancer Research Centre Newcastle University Newcastle UK
r Department of Pediatric Oncology and Hematology University of Cologne Cologne Germany
s European Medicines Agency London UK
w Pediatric Hematology Oncology Unit Antwerp University Hospital Antwerp Belgium
x Department of Clinical Research Gustave Roussy Paris Sud University Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17030757
- 003
- CZ-PrNML
- 005
- 20171101111409.0
- 007
- ta
- 008
- 171025s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/17460441.2017.1340269 $2 doi
- 035 __
- $a (PubMed)28604107
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Moreno, Lucas $u a Paediatric Phase I-II Clinical Trials Unit, Paediatric Haematology & Oncology , Hospital Niño Jesus , Madrid , Spain. b Instituto de Investigación Sanitaria La Princesa , Madrid , Spain. c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK.
- 245 10
- $a Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project / $c L. Moreno, H. Caron, B. Geoerger, A. Eggert, G. Schleiermacher, P. Brock, D. Valteau-Couanet, L. Chesler, JH. Schulte, K. De Preter, J. Molenaar, A. Schramm, M. Eilers, T. Van Maerken, JI. Johnsen, M. Garrett, SL. George, DA. Tweddle, P. Kogner, F. Berthold, J. Koster, G. Barone, ER. Tucker, L. Marshall, R. Herold, J. Sterba, K. Norga, G. Vassal, AD. Pearson,
- 520 9_
- $a INTRODUCTION: Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively small numbers of patients. Areas covered: The current drug development model has been slow, associated with significant attrition, and few new drugs have been developed for neuroblastoma. The Neuroblastoma New Drug Development Strategy (NDDS) has: 1) established a group with expertise in drug development; 2) prioritised targets and drugs according to tumour biology (target expression, dependency, pre-clinical data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3) promoted clinical trials with target-prioritised drugs. Drugs showing activity can be rapidly transitioned via parallel randomised trials into front-line studies. Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a protinádorové látky $x škodlivé účinky $x farmakologie $7 D000970
- 650 _2
- $a dítě $7 D002648
- 650 12
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a preklinické hodnocení léčiv $x metody $7 D004353
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a neuroblastom $x farmakoterapie $x patologie $7 D009447
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Caron, Hubert $u d Emma Children's Hospital , Amsterdam , Netherlands. e Hoffman-La Roche , Basel , Switzerland.
- 700 1_
- $a Geoerger, Birgit $u f Department of Paediatric and Adolescent Oncology , Institut Gustave Roussy , Villejuif , France.
- 700 1_
- $a Eggert, Angelika $u g Department of Pediatric Oncology and Hematology , Charite University Hospital , Berlin , Germany.
- 700 1_
- $a Schleiermacher, Gudrun $u h Department of Paediatric, Adolescents and Young Adults Oncology and INSERM U830 , Institut Curie , Paris , France.
- 700 1_
- $a Brock, Penelope $u i Department Paediatric Oncology , Great Ormond Street Hospital , London , UK.
- 700 1_
- $a Valteau-Couanet, Dominique $u f Department of Paediatric and Adolescent Oncology , Institut Gustave Roussy , Villejuif , France.
- 700 1_
- $a Chesler, Louis $u c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK. j Division of Clinical Studies , Institute of Cancer Research , London , UK.
- 700 1_
- $a Schulte, Johannes H $u g Department of Pediatric Oncology and Hematology , Charite University Hospital , Berlin , Germany.
- 700 1_
- $a De Preter, Katleen $u k Centre for Medical Genetic , Ghent University , Ghent , Belgium.
- 700 1_
- $a Molenaar, Jan $u l Princess Maxima Center for Pediatric Oncology , University of Amsterdam , Amsterdam , Netherlands.
- 700 1_
- $a Schramm, Alexander $u m Department of Pediatric Oncology , University of Essen , Essen , Germany.
- 700 1_
- $a Eilers, Martin $u n Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter , University of Wurzburg , Wurzburg , Germany.
- 700 1_
- $a Van Maerken, Tom $u k Centre for Medical Genetic , Ghent University , Ghent , Belgium.
- 700 1_
- $a Johnsen, John Inge $u o Department of Women's and Children's Health , Karolinska Institute , Stockholm , Sweden.
- 700 1_
- $a Garrett, Michelle $u p School of Biosciences , University of Kent , Canterbury , UK.
- 700 1_
- $a George, Sally L $u c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK. j Division of Clinical Studies , Institute of Cancer Research , London , UK.
- 700 1_
- $a Tweddle, Deborah A $u q Wolfson Childhood Cancer Research Centre , Newcastle University , Newcastle , UK.
- 700 1_
- $a Kogner, Per $u o Department of Women's and Children's Health , Karolinska Institute , Stockholm , Sweden.
- 700 1_
- $a Berthold, Frank $u r Department of Pediatric Oncology and Hematology , University of Cologne , Cologne , Germany.
- 700 1_
- $a Koster, Jan $u l Princess Maxima Center for Pediatric Oncology , University of Amsterdam , Amsterdam , Netherlands.
- 700 1_
- $a Barone, Giuseppe $u c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK. j Division of Clinical Studies , Institute of Cancer Research , London , UK.
- 700 1_
- $a Tucker, Elizabeth R $u c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK. j Division of Clinical Studies , Institute of Cancer Research , London , UK.
- 700 1_
- $a Marshall, Lynley $u c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK. j Division of Clinical Studies , Institute of Cancer Research , London , UK.
- 700 1_
- $a Herold, Ralf $u s European Medicines Agency , London , UK.
- 700 1_
- $a Sterba, Jaroslav $u t Masaryk University, University Hospital , Brno , Czech Republic. u Department of Pediatric Oncology , International Clinical Research Center, St. Anne's University Hospital , Brno , Czech Republic. v RECAMO, Masaryk Memorial Cancer Centre , Brno , Czech Republic.
- 700 1_
- $a Norga, Koen $u w Pediatric Hematology/Oncology Unit , Antwerp University Hospital , Antwerp , Belgium.
- 700 1_
- $a Vassal, Gilles $u x Department of Clinical Research, Gustave Roussy , Paris-Sud University , Paris , France.
- 700 1_
- $a Pearson, Andrew Dj $u c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK. j Division of Clinical Studies , Institute of Cancer Research , London , UK.
- 773 0_
- $w MED00181710 $t Expert opinion on drug discovery $x 1746-045X $g Roč. 12, č. 8 (2017), s. 801-811
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28604107 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171101111501 $b ABA008
- 999 __
- $a ok $b bmc $g 1254350 $s 991784
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 12 $c 8 $d 801-811 $e 20170626 $i 1746-045X $m Expert opinion on drug discovery $n Expert Opin Drug Discov $x MED00181710
- LZP __
- $a Pubmed-20171025
